The Pharmaceutical Marketing Group

Editor’s Pick

UK rejects adult Novartis CAR-T therapy, after ‘yes’ in kids

Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people.

Bayer’s Monsanto asks U.S. court to toss $289 million glyphosate verdict

Bayer AG unit Monsanto on Tuesday asked a California judge to throw out a $289 million jury verdict awarded to a man who alleged the company's glyphosate-based weed-killers, including Roundup, gave him cancer.

AstraZeneca plots China robot offensive to counter price cuts

With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.

California insurance regulator sues AbbVie alleging Humira kickbacks

Insurance Commissioner Dave Jones on Tuesday filed a complaint on behalf of the State of California against AbbVie Inc, alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira.

GSK grabs new drug development head from Boehringer

GlaxoSmithKline has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research strategy, a spokesman for the British group said on Tuesday.

Harvard Professor’s Attack On Pharma’s Clinical Trials Is Absurd

Dr. Marcia Angell, a senior lecturer at Harvard Medical School and the first woman to serve as editor-in-chief of The New England Journal of Medicine, has long been a critic of the pharmaceutical industry. This industry is far from immune to criticism, nor should it be. However, Dr. Angell’s critiques tend to expose her lack of knowledge of the workings of the drug R&D process and the important relationship that exists between academia and industry.

U.S. Department of Justice Grants Clearance to Cigna’s Acquisition of Express Scripts

BLOOMFIELD, Conn. & ST. LOUIS–(BUSINESS WIRE)–Cigna Corporation (NYSE: CI) (“Cigna”) and Express Scripts Holding Company (NASDAQ: ESRX) (“Express Scripts”) today announced that the Antitrust Division of the United States Department of Justice (DOJ) has cleared their pending merger, terminating the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. “We are pleased that the Department of Justice has cleared our transaction and that we are another step closer to completing our merger and delivering greater affordability, choice and predictability to our customers and clients as a combined company,” said David Cordani, President and Chief Executive Officer of Cigna. “The value that we deliver together will help put our society on a far mor...

California Life Sciences Association Urges Governor Jerry Brown to Sign Legislation to Protect Clinical Trials and Patient Access in California

SACRAMENTO, Calif.–(BUSINESS WIRE)–California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today urged Governor Jerry Brown to sign Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and awaits action by Governor Brown, who has until Sept. 30 to sign or veto the legislation. “For many Californians, clinical trials are the last best option for accessing life-saving and life-sustaining treatments. Unfortunately, AB 375, California’s recently passed data privacy law could inadvertently prevent patients from accessing the innovative c...

Viking Therapeutics liver drug succeeds in mid-stage study

Viking Therapeutics Inc said on Tuesday its experimental liver disease treatment met the main goals of a mid-stage trial by reducing cholesterol and liver fat in patients.

Congenica Announces Market Access Partnership with Digital China Health to Enable Genomic Medicine in the Chinese Market

CAMBRIDGE, England–(BUSINESS WIRE)–Congenica, the global diagnostic decision support platform provider, today announced it has entered into an agreement with a new strategic partner Digital China Health Technologies Cooperation Limited (DCHealth), further extending Congenica’s commitment to the Chinese market. The new partnership will see Congenica develop a version of its Sapientia™ platform designed to enable clinicians and patients in China to benefit from the clinical genomics and personalised medicine revolution. DCHealth will use its significant commercial depth and experience in the Chinese hospital market to accelerate the commercialization of this locally-adapted version of Sapientia™. A leading player in the fast-emerging genomics medicines space, Congenica’s Sapienti...

Clinical trial data for nintedanib in patients with advanced IPF published

INGELHEIM, Germany–(BUSINESS WIRE)–Results from the INSTAGE® trial have been presented at the 2018 European Respiratory Society (ERS) conference in Paris and published in the New England Journal of Medicine.1 The trial reports clinical data on a subset of patients with IPF and severe impairment in gas exchange, for whom only limited data exist. Data suggest that the efficacy and safety profiles of nintedanib in INSTAGE® were consistent with the profiles observed in patients with less advanced disease in the INPULSIS® and TOMORROW trials.1,2,4 INSTAGE® was conducted to investigate the efficacy and safety of nintedanib plus sildenafil vs. nintedanib monotherapy in patients with IPF and severely impaired gas exchange (DLco ≤ 35% predicted), who have largely been excluded from prev...

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

INGELHEIM, Germany--(BUSINESS WIRE)--Results from INPULSIS®-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of Ofev® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF).1 These data suggest that the effect of nintedanib on slowing disease progression of IPF persists beyond four years.1 Results also indicate that the long-term efficacy of nintedanib in reducing disease progression may be sustained in patients